Liu Lei, Zhang Qiao, Jin Shuai, Xie Lang
School of Biology & Engineering (School of Health Medicine Modern Industry), Guizhou Medical University, Guiyang, 561113, China.
Medical Department, The Second People's Hospital of Guiyang(Jinyang Hospital), Guiyang, 550081, China.
World J Surg Oncol. 2024 Dec 28;22(1):351. doi: 10.1186/s12957-024-03639-4.
INTRODUCTION: Although the Tumor-Node-Metastasis (TNM) staging system is widely used for staging lung squamous cell carcinoma (LSCC), the TNM system primarily emphasizes tumor size and metastasis, without adequately considering lymph node involvement. Consequently, incorporating lymph node metastasis as an additional prognostic factor is essential for predicting outcomes in LSCC patients. METHODS: This retrospective study included patients diagnosed with LSCC between 2004 and 2018 and was based on data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. The primary endpoint of the study was cancer-specific survival (CSS), and demographic characteristics, tumor characteristics, and treatment regimens were incorporated into the predictive model. The study focused on the value of indicators related to pathological lymph node testing, including the lymph node ratio (LNR), regional node positivity (RNP), and lymph node examination count (RNE), in the prediction of cancer-specific survival in LSCC. A prognostic model was established using a multivariate Cox regression model, and the model was evaluated using the C index, Kaplan-Meier, the Akaike information criterion (AIC), decision curve analysis (DCA), continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI), and the predictive efficacy of different models was compared. RESULTS: A total of 14,200 LSCC patients (2004-2018) were divided into training and validation cohorts. The 10-year CSS rate was approximately 50%, with no significant survival differences between cohorts (p = 0.8). The prognostic analysis revealed that models incorporating LNR, RNP, and RNE demonstrated superior performance over the TNM model. The LNR and RNP models demonstrated better model fit, discrimination, and reclassification, with AUC values of 0.695 (training) and 0.665 (validation). The RNP and LNR models showed similar predictive performance, significantly outperforming the TNM and RNE models. Calibration curves and decision curve analysis confirmed the clinical utility and net benefit of the LNR and RNP models in predicting long-term CSS for LSCC patients, highlighting their value in clinical decision-making. CONCLUSION: This study confirms that RNP status is an independent prognostic factor for CSS in LSCC, with predictive efficacy comparable to LNR, with both models enhancing survival prediction beyond TNM staging.
引言:尽管肿瘤-淋巴结-转移(TNM)分期系统广泛用于肺鳞状细胞癌(LSCC)的分期,但TNM系统主要强调肿瘤大小和转移情况,未充分考虑淋巴结受累情况。因此,将淋巴结转移作为额外的预后因素对于预测LSCC患者的预后至关重要。 方法:这项回顾性研究纳入了2004年至2018年间被诊断为LSCC的患者,数据来自美国国立癌症研究所的监测、流行病学和最终结果(SEER)数据库。该研究的主要终点是癌症特异性生存(CSS),并将人口统计学特征、肿瘤特征和治疗方案纳入预测模型。该研究重点关注与病理淋巴结检测相关指标的价值,包括淋巴结比率(LNR)、区域淋巴结阳性率(RNP)和淋巴结检查计数(RNE),用于预测LSCC患者的癌症特异性生存。使用多变量Cox回归模型建立预后模型,并使用C指数、Kaplan-Meier、赤池信息准则(AIC)、决策曲线分析(DCA)、连续净重新分类改善(NRI)和综合判别改善(IDI)对模型进行评估,并比较不同模型的预测效能。 结果:共有14200例LSCC患者(2004 - 2018年)被分为训练队列和验证队列。10年CSS率约为50%,各队列之间的生存差异无统计学意义(p = 0.8)。预后分析显示,纳入LNR、RNP和RNE的模型表现优于TNM模型。LNR和RNP模型显示出更好的模型拟合、判别能力和重新分类能力,训练集AUC值为0.695,验证集为0.665。RNP和LNR模型显示出相似的预测性能,显著优于TNM和RNE模型。校准曲线和决策曲线分析证实了LNR和RNP模型在预测LSCC患者长期CSS方面的临床实用性和净效益,突出了它们在临床决策中的价值。 结论:本研究证实RNP状态是LSCC患者CSS的独立预后因素,其预测效能与LNR相当,这两种模型均能增强TNM分期之外的生存预测能力。
World J Surg Oncol. 2024-12-28
World J Surg. 2021-1
Clin Orthop Relat Res. 2019-11
Trends Mol Med. 2019-5-30